医药生物行业周报:自免迈入后DUPI时代 关注POC率先验证的TSLP类自免双抗

中邮证券
Sep 15, 2025

本周主题本周我们探讨自免领域的双抗的投资机会。自免药物明显的特征在于人数多、DOT 长,往往能诞生多个blockbuster。因而对于下一个blockbuster 思考的核心方向在于:现有疗法下自免领域亟待解决的未满足需求是什么?以及什么样的药物最有可能率先满足这些需求?我们认为长效化、疗效提升、惠及更大的人群系现有疗法下仍未满足的需求。而双抗在成药把握性和双靶点的协同疗效上具备机制上的优势。同时...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10